Alaa Abuquta

Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men

Dong Liu, Jian Li, S. Hannawi, 2023, Nature communications.

Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trial

S. Hannawi, Lixin Yan, A. Alamadi, 2023, EClinicalMedicine.

Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trial

S. Hannawi, Liangzhi Xie, Lixin Yan, 2022, eBioMedicine.

Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C in adults previously vaccinated with inactivated vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trial

Jian Li, S. Hannawi, Liangzhi Xie, 2022, Journal of Infection.

Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies.

Jing-xin Li, A. Alamadi, Aala Hassan, 2024, Expert review of vaccines.

Safety and immunogenicity of boosting with a severe acute respiratory syndrome coronavirus 2 omicron variant mRNA vaccine in healthy adults: An open‐label, and single‐arm Phase 1 study

C. Qin, S. Hannawi, Rong-Rong Zhang, 2023, Clinical and translational medicine.

Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine.

C. Qin, S. Hannawi, B. Ying, 2024, Cell Discovery.